A Phase II Randomized, Double-Blind, Multicenter Study to Evaluate Efficacy and Safety of Intravenous Iclaprim Versus Vancomycin for the Treatment of Nosocomial Pneumonia Suspected or Confirmed to be Due to Gram-Positive Pathogens

Huang, DB, File, TM, Torres, A et al. (5 more authors) (2017) A Phase II Randomized, Double-Blind, Multicenter Study to Evaluate Efficacy and Safety of Intravenous Iclaprim Versus Vancomycin for the Treatment of Nosocomial Pneumonia Suspected or Confirmed to be Due to Gram-Positive Pathogens. Clinical Therapeutics, 39 (8). pp. 1706-1718. ISSN 0149-2918

Abstract

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: © 2017 Elsevier Inc. This is an author produced version of a paper published in Clinical Therapeutics. Uploaded in accordance with the publisher's self-archiving policy.
Keywords: iclaprim; nosocomial pneumonia; vancomycin
Dates:
  • Published: August 2017
  • Accepted: 5 July 2017
  • Published (online): 27 July 2017
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > Institute of Molecular Medicine (LIMM) (Leeds) > Section of Molecular Gastroenterology (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 31 Jul 2017 13:22
Last Modified: 27 Jul 2018 00:38
Status: Published
Publisher: Elsevier
Identification Number: https://doi.org/10.1016/j.clinthera.2017.07.007

Share / Export

Statistics